Company intelligence / Profile preview

SGX Pharmaceuticals, Inc.

San Diego, California, United Statessec.gov ↗

Ownership: Private
Development stage: Phase 3

Overview

SGX Pharmaceuticals was a biotechnology company focused on discovering, developing, and commercializing small molecule drugs for the treatment of cancer, utilizing its proprietary FAST™ platform and X-ray crystallography for structure-based drug design.

Therapeutic areas: Oncology
Modalities: Small molecules[5]Protein kinase inhibitors[3]
Industry: Biotech

Drug pipeline

1 asset

troxacitabine

Phase 3

Indications: Acute Myelogenous Leukemia, Myelodysplastic Syndromes, Solid tumors

Beyond the preview

Go deeper on SGX Pharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SGX Pharmaceuticals, Inc..

Explore the full profile